EPS for ViewRay, Inc. (VRAY) Expected At $-0.15

February 20, 2018 - By Louis Casey

 EPS for ViewRay, Inc. (VRAY) Expected At $ 0.15

Analysts expect ViewRay, Inc. (NASDAQ:VRAY) to report $-0.15 EPS on March, 15.They anticipate $0.10 EPS change or 40.00 % from last quarter’s $-0.25 EPS. After having $-0.19 EPS previously, ViewRay, Inc.’s analysts see -21.05 % EPS growth. The stock increased 0.36% or $0.03 during the last trading session, reaching $8.41. About 358,847 shares traded. ViewRay, Inc. (NASDAQ:VRAY) has risen 34.94% since February 20, 2017 and is uptrending. It has outperformed by 18.24% the S&P500.

ViewRay, Inc., through its subsidiary, ViewRay Technologies, Inc., designs, makes, and markets radiation therapy systems. The company has market cap of $568.97 million. It offers MRIdian, a radiation therapy solution that enables treatment and real-time imaging of a patient's anatomy simultaneously. It currently has negative earnings. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered.

More news for ViewRay, Inc. (NASDAQ:VRAY) were recently published by: Prnewswire.com, which released: “ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors” on February 07, 2018. Gurufocus.com‘s article titled: “Fosun International Ltd Buys ViewRay Inc, Colony NorthStar Inc, iKang …” and published on February 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.